Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 206

1.

Higher doses of naloxone are needed in the synthetic opiod era.

Moss RB, Carlo DJ.

Subst Abuse Treat Prev Policy. 2019 Feb 18;14(1):6. doi: 10.1186/s13011-019-0195-4.

2.

Sweat rate analysis of ivacaftor potentiation of CFTR in non-CF adults.

Kim J, Farahmand M, Dunn C, Milla CE, Horii RI, Thomas EAC, Moss RB, Wine JJ.

Sci Rep. 2018 Nov 2;8(1):16233. doi: 10.1038/s41598-018-34308-8.

3.

Human factors study of a newly approved prefilled syringe of epinephrine for the treatment of anaphylaxis.

Moss RB, Moll T, Daniels K, Carlo DJ.

Allergy Asthma Proc. 2018 Sep 1;39(5):389-393. doi: 10.2500/aap.2018.39.4154.

PMID:
30153890
4.

The myriad challenges of respiratory fungal infection in cystic fibrosis.

Tracy MC, Moss RB.

Pediatr Pulmonol. 2018 Nov;53(S3):S75-S85. doi: 10.1002/ppul.24126. Epub 2018 Jul 10. Review.

PMID:
29992775
5.

Anaphylaxis: getting to the point (and price) of diagnosis and treatment.

Moss RB.

J Asthma Allergy. 2018 Jun 20;11:109-110. doi: 10.2147/JAA.S170650. eCollection 2018. No abstract available.

6.

Resistin is elevated in cystic fibrosis sputum and correlates negatively with lung function.

Forrest OA, Chopyk DM, Gernez Y, Brown MR, Conrad CK, Moss RB, Tangpricha V, Peng L, Tirouvanziam R.

J Cyst Fibros. 2019 Jan;18(1):64-70. doi: 10.1016/j.jcf.2018.05.018. Epub 2018 Jun 21.

PMID:
29937317
7.

Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.

Burgener EB, Moss RB.

Curr Opin Pediatr. 2018 Jun;30(3):372-377. doi: 10.1097/MOP.0000000000000627. Review.

8.

Human factors study in untrained adolescents comparing a recently approved single-dose epinephrine prefilled syringe with an approved autoinjector.

Moss RB, Daniels K, Moll T, Carlo DJ.

Ann Allergy Asthma Immunol. 2018 May;120(5):540-541. doi: 10.1016/j.anai.2018.02.027. Epub 2018 Feb 27. No abstract available.

9.

Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation.

Wagener JS, Millar SJ, Mayer-Hamblett N, Sawicki GS, McKone EF, Goss CH, Konstan MW, Morgan WJ, Pasta DJ, Moss RB.

J Cyst Fibros. 2018 Jul;17(4):503-510. doi: 10.1016/j.jcf.2017.10.003. Epub 2017 Oct 31.

10.

Small Colony Variants of Pseudomonas aeruginosa Display Heterogeneity in Inhibiting Aspergillus fumigatus Biofilm.

Anand R, Moss RB, Sass G, Banaei N, Clemons KV, Martinez M, Stevens DA.

Mycopathologia. 2018 Feb;183(1):263-272. doi: 10.1007/s11046-017-0186-9. Epub 2017 Aug 7.

PMID:
28785939
11.

Susceptibility of Candida albicans from Cystic Fibrosis Patients.

Sabino R, Carolino E, Moss RB, Banaei N, Verissimo C, Stevens DA.

Mycopathologia. 2017 Oct;182(9-10):863-867. doi: 10.1007/s11046-017-0133-9. Epub 2017 Apr 18.

PMID:
28421452
12.

The magnitude of ivacaftor effects on fluid secretion via R117H-CFTR channels: Human in vivo measurements.

Char JE, Dunn C, Davies Z, Milla C, Moss RB, Wine JJ.

PLoS One. 2017 Apr 18;12(4):e0175486. doi: 10.1371/journal.pone.0175486. eCollection 2017.

13.

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.

Konstan MW, McKone EF, Moss RB, Marigowda G, Tian S, Waltz D, Huang X, Lubarsky B, Rubin J, Millar SJ, Pasta DJ, Mayer-Hamblett N, Goss CH, Morgan W, Sawicki GS.

Lancet Respir Med. 2017 Feb;5(2):107-118. doi: 10.1016/S2213-2600(16)30427-1. Epub 2016 Dec 21.

PMID:
28011037
14.

Are Cystic Fibrosis Aspergillus fumigatus Isolates Different? Intermicrobial Interactions with Pseudomonas.

Nazik H, Moss RB, Karna V, Clemons KV, Banaei N, Cohen K, Choudhary V, Stevens DA.

Mycopathologia. 2017 Apr;182(3-4):315-318. doi: 10.1007/s11046-016-0087-3. Epub 2016 Nov 7.

PMID:
27822731
15.

Allergic Bronchopulmonary Aspergillosis.

Tracy MC, Okorie CUA, Foley EA, Moss RB.

J Fungi (Basel). 2016 Jun 6;2(2). pii: E17. doi: 10.3390/jof2020017. Review.

16.

Earth Mover's Distance (EMD): A True Metric for Comparing Biomarker Expression Levels in Cell Populations.

Orlova DY, Zimmerman N, Meehan S, Meehan C, Waters J, Ghosn EE, Filatenkov A, Kolyagin GA, Gernez Y, Tsuda S, Moore W, Moss RB, Herzenberg LA, Walther G.

PLoS One. 2016 Mar 23;11(3):e0151859. doi: 10.1371/journal.pone.0151859. eCollection 2016.

17.

DAS181 Treatment of Severe Parainfluenza Virus 3 Pneumonia in Allogeneic Hematopoietic Stem Cell Transplant Recipients Requiring Mechanical Ventilation.

Dhakal B, D'Souza A, Pasquini M, Saber W, Fenske TS, Moss RB, Drobyski WR, Hari P, Abidi MZ.

Case Rep Med. 2016;2016:8503275. doi: 10.1155/2016/8503275. Epub 2016 Jan 28.

18.

DAS181 for Treatment of Parainfluenza Virus Infections in Hematopoietic Stem Cell Transplant Recipients at a Single Center.

Salvatore M, Satlin MJ, Jacobs SE, Jenkins SG, Schuetz AN, Moss RB, Van Besien K, Shore T, Soave R.

Biol Blood Marrow Transplant. 2016 May;22(5):965-70. doi: 10.1016/j.bbmt.2016.02.011. Epub 2016 Feb 22.

19.

Enterovirus 68 Infection--Association with Asthma.

Moss RB.

J Allergy Clin Immunol Pract. 2016 Mar-Apr;4(2):226-8. doi: 10.1016/j.jaip.2015.12.013. Epub 2016 Feb 1. Review.

PMID:
26843407
20.

Treating allergic bronchopulmonary aspergillosis: the way forward.

Moss RB.

Eur Respir J. 2016 Feb;47(2):385-7. doi: 10.1183/13993003.01816-2015. No abstract available.

21.

Effect of Media Modified To Mimic Cystic Fibrosis Sputum on the Susceptibility of Aspergillus fumigatus, and the Frequency of Resistance at One Center.

Stevens DA, Moss RB, Hernandez C, Clemons KV, Martinez M.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2180-4. doi: 10.1128/AAC.02649-15. Print 2016 Apr.

22.

Blood basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis in cystic fibrosis.

Gernez Y, Waters J, Mirković B, Lavelle GM, Dunn CE, Davies ZA, Everson C, Tirouvanziam R, Silver E, Wallenstein S, Chotirmall SH, McElvaney NG, Herzenberg LA, Moss RB.

Eur Respir J. 2016 Jan;47(1):177-85. doi: 10.1183/13993003.01068-2015. Epub 2015 Nov 19. Erratum in: Eur Respir J. 2016 Jun;47(6):1892.

23.

Emergence of Hemagglutinin Mutations During the Course of Influenza Infection.

Cushing A, Kamali A, Winters M, Hopmans ES, Bell JM, Grimes SM, Xia LC, Zhang NR, Moss RB, Holodniy M, Ji HP.

Sci Rep. 2015 Nov 5;5:16178. doi: 10.1038/srep16178.

24.

The basophil surface marker CD203c identifies Aspergillus species sensitization in patients with cystic fibrosis.

Mirković B, Lavelle GM, Azim AA, Helma K, Gargoum FS, Molloy K, Gernez Y, Dunne K, Renwick J, Murphy P, Moss RB, Greene CM, Gunaratnam C, Chotirmall SH, McElvaney NG.

J Allergy Clin Immunol. 2016 Feb;137(2):436-443.e9. doi: 10.1016/j.jaci.2015.07.045. Epub 2015 Sep 18.

PMID:
26388311
25.

Inhibition of Aspergillus fumigatus and Its Biofilm by Pseudomonas aeruginosa Is Dependent on the Source, Phenotype and Growth Conditions of the Bacterium.

Ferreira JA, Penner JC, Moss RB, Haagensen JA, Clemons KV, Spormann AM, Nazik H, Cohen K, Banaei N, Carolino E, Stevens DA.

PLoS One. 2015 Aug 7;10(8):e0134692. doi: 10.1371/journal.pone.0134692. eCollection 2015.

26.

Treatment of resistant influenza virus infection in a hospitalized patient with cystic fibrosis with DAS181, a host-directed antiviral.

Silveira FP, Abdel-Massih R, Bogdanovich T, Pakstis DL, Routh RL, Moss RB.

Antivir Ther. 2016;21(1):71-4. doi: 10.3851/IMP2977. Epub 2015 Jul 2.

PMID:
26133231
27.

Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.

Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, Rubenstein RC, Higgins M; VX11-770-110 (KONDUCT) Study Group.

Lancet Respir Med. 2015 Jul;3(7):524-33. doi: 10.1016/S2213-2600(15)00201-5. Epub 2015 Jun 9.

28.

Recent advances in cystic fibrosis.

Milla CE, Moss RB.

Curr Opin Pediatr. 2015 Jun;27(3):317-24. doi: 10.1097/MOP.0000000000000226. Review.

PMID:
25888148
29.

Fungi in cystic fibrosis and non-cystic fibrosis bronchiectasis.

Moss RB.

Semin Respir Crit Care Med. 2015 Apr;36(2):207-16. doi: 10.1055/s-0035-1546750. Epub 2015 Mar 31. Review.

PMID:
25826588
30.

Molecular epidemiology of Aspergillus collected from cystic fibrosis patients.

Sabino R, Ferreira JA, Moss RB, Valente J, Veríssimo C, Carolino E, Clemons KV, Everson C, Banaei N, Penner J, Stevens DA.

J Cyst Fibros. 2015 Jul;14(4):474-81. doi: 10.1016/j.jcf.2014.10.005. Epub 2014 Oct 30.

31.

Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial.

Conrad C, Lymp J, Thompson V, Dunn C, Davies Z, Chatfield B, Nichols D, Clancy J, Vender R, Egan ME, Quittell L, Michelson P, Antony V, Spahr J, Rubenstein RC, Moss RB, Herzenberg LA, Goss CH, Tirouvanziam R.

J Cyst Fibros. 2015 Mar;14(2):219-27. doi: 10.1016/j.jcf.2014.08.008. Epub 2014 Sep 13.

32.

A little CFTR goes a long way: CFTR-dependent sweat secretion from G551D and R117H-5T cystic fibrosis subjects taking ivacaftor.

Char JE, Wolfe MH, Cho HJ, Park IH, Jeong JH, Frisbee E, Dunn C, Davies Z, Milla C, Moss RB, Thomas EA, Wine JJ.

PLoS One. 2014 Feb 10;9(2):e88564. doi: 10.1371/journal.pone.0088564. eCollection 2014.

33.

DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation.

Chalkias S, Mackenzie MR, Gay C, Dooley C, Marty FM, Moss RB, Li T, Routh RL, Walsh SR, Tan CS.

Transpl Infect Dis. 2014 Feb;16(1):141-4. doi: 10.1111/tid.12177. Epub 2014 Jan 3.

34.

Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis.

Moss RB.

Eur Respir J. 2014 May;43(5):1487-500. doi: 10.1183/09031936.00139513. Epub 2013 Dec 5. Review.

35.

The use of sialidase therapy for respiratory viral infections.

Nicholls JM, Moss RB, Haslam SM.

Antiviral Res. 2013 Jun;98(3):401-9. doi: 10.1016/j.antiviral.2013.04.012. Epub 2013 Apr 17. Review.

PMID:
23602850
36.

Current treatment options for invasive aspergillosis.

Batista MV, Costa SF, Shikanai-Yasuda MA, Moss RB.

Drugs Today (Barc). 2013 Mar;49(3):213-26. doi: 10.1358/dot.2013.49.3.1921234. Review.

PMID:
23527325
37.

Pitfalls of drug development: lessons learned from trials of denufosol in cystic fibrosis.

Moss RB.

J Pediatr. 2013 Apr;162(4):676-80. doi: 10.1016/j.jpeds.2012.11.034. Epub 2013 Jan 3. No abstract available.

PMID:
23290508
38.

DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient.

Drozd DR, Limaye AP, Moss RB, Sanders RL, Hansen C, Edelman JD, Raghu G, Boeckh M, Rakita RM.

Transpl Infect Dis. 2013 Feb;15(1):E28-32. doi: 10.1111/tid.12045. Epub 2012 Dec 26.

PMID:
23279859
39.

The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis.

Moss RB.

Ann N Y Acad Sci. 2012 Dec;1272:49-57. doi: 10.1111/j.1749-6632.2012.06810.x.

PMID:
23231714
40.

A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection.

Moss RB, Hansen C, Sanders RL, Hawley S, Li T, Steigbigel RT.

J Infect Dis. 2012 Dec 15;206(12):1844-51. doi: 10.1093/infdis/jis622. Epub 2012 Oct 8.

41.

Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis.

Moss RB, Mistry SJ, Konstan MW, Pilewski JM, Kerem E, Tal-Singer R, Lazaar AL; CF2110399 Investigators.

J Cyst Fibros. 2013 May;12(3):241-8. doi: 10.1016/j.jcf.2012.08.016. Epub 2012 Sep 17.

42.

Long term effects of denufosol tetrasodium in patients with cystic fibrosis.

Ratjen F, Durham T, Navratil T, Schaberg A, Accurso FJ, Wainwright C, Barnes M, Moss RB; TIGER-2 Study Investigator Group.

J Cyst Fibros. 2012 Dec;11(6):539-49. doi: 10.1016/j.jcf.2012.05.003. Epub 2012 Jun 8.

43.

Blood basophils from cystic fibrosis patients with allergic bronchopulmonary aspergillosis are primed and hyper-responsive to stimulation by aspergillus allergens.

Gernez Y, Dunn CE, Everson C, Mitsunaga E, Gudiputi L, Krasinska K, Davies ZA, Herzenberg LA, Tirouvanziam R, Moss RB.

J Cyst Fibros. 2012 Dec;11(6):502-10. doi: 10.1016/j.jcf.2012.04.008. Epub 2012 May 16.

44.

Perspective: emerging challenges in the treatment of influenza and parainfluenza in transplant patients.

Moss RB, Steigbigel RT, Sanders RL, Fang F.

Adv Virol. 2011;2011:910930. doi: 10.1155/2011/910930. Epub 2011 Jul 7.

45.

Fungi and allergic lower respiratory tract diseases.

Knutsen AP, Bush RK, Demain JG, Denning DW, Dixit A, Fairs A, Greenberger PA, Kariuki B, Kita H, Kurup VP, Moss RB, Niven RM, Pashley CH, Slavin RG, Vijay HM, Wardlaw AJ.

J Allergy Clin Immunol. 2012 Feb;129(2):280-91; quiz 292-3. doi: 10.1016/j.jaci.2011.12.970. Review.

PMID:
22284927
46.

Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation.

Chen YB, Driscoll JP, McAfee SL, Spitzer TR, Rosenberg ES, Sanders R, Moss RB, Fang F, Marty FM.

Clin Infect Dis. 2011 Oct;53(7):e77-80. doi: 10.1093/cid/cir501. Epub 2011 Aug 31.

PMID:
21880586
47.

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.

Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, De Boeck K, Donaldson SH, Dorkin HL, Dunitz JM, Durie PR, Jain M, Leonard A, McCoy KS, Moss RB, Pilewski JM, Rosenbluth DB, Rubenstein RC, Schechter MS, Botfield M, Ordoñez CL, Spencer-Green GT, Vernillet L, Wisseh S, Yen K, Konstan MW.

Thorax. 2012 Jan;67(1):12-8. doi: 10.1136/thoraxjnl-2011-200393. Epub 2011 Aug 8.

48.

Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function.

Accurso FJ, Moss RB, Wilmott RW, Anbar RD, Schaberg AE, Durham TA, Ramsey BW; TIGER-1 Investigator Study Group.

Am J Respir Crit Care Med. 2011 Mar 1;183(5):627-34. doi: 10.1164/rccm.201008-1267OC. Epub 2010 Dec 17.

PMID:
21169471
49.

Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.

Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewski JM, Rubenstein RC, Uluer AZ, Aitken ML, Freedman SD, Rose LM, Mayer-Hamblett N, Dong Q, Zha J, Stone AJ, Olson ER, Ordoñez CL, Campbell PW, Ashlock MA, Ramsey BW.

N Engl J Med. 2010 Nov 18;363(21):1991-2003. doi: 10.1056/NEJMoa0909825.

50.

Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis.

Moss RB.

Curr Opin Pulm Med. 2010 Nov;16(6):598-603. doi: 10.1097/MCP.0b013e32833e24a6. Review.

PMID:
20720494

Supplemental Content

Support Center